The novel anti-folate receptor alpha (FolRα) antibody-drug conjugate (ADC) STRO-002 demonstrated encouraging efficacy with a tolerable safety profile in patients with advanced platinum-resistant or refractory epithelial ovarian cancer, according to updated interim results from the phase 1 STRO-002-GM1 trial (NCT03748186).1 READ MORE…

One of the ongoing bigger concerns for hospitalist clinicians when treating patients with severe COVID-19 is having them avoid or minimize the cytokine storm. Patients experiencing this can see their conditions worsen and can lead to greater complications and possibly death. La Jolla-Calif.,-based INmune Bio is a clinical-stage immunology company, which has been developing a […]

Researchers at UNMC are at it again. Two years ago, FOX 42 News was there as treatments were worked on to make the fight against cancer easier. Now, we’ve learned a new agreement paving the way for clinical trials of a Coronavirus vaccine is getting worked out. “We have to do everything we can against […]